I
IDEAYA Biosciences, Inc. (IDYA)
NMS – Real Time Price. Currency in USD
30.46
-1.63 (-5.08%)
At close: Mar 27, 2026, 4:00 PM EDT
30.46
0.00 (0.00%)
After-hours: Mar 27, 2026, 4:34 PM EDT
Get all premium features to the best stock analysis tool
NMS – Real Time Price. Currency in USD
30.46
-1.63 (-5.08%)
At close: Mar 27, 2026, 4:00 PM EDT
30.46
0.00 (0.00%)
After-hours: Mar 27, 2026, 4:34 PM EDT
No Data
There are no news for this stock.
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 11.34 | 6.05 | 10 | |
| Quick ratio | 11.34 | 5.63 | 10 | |
| Debt to Equity | 0.03 | 0.30 | 9.0 | |
| Debt to Assets | 0.03 | 1.04 | 9.0 | |
| Interest coverage | N/A | -16.91 | 1.0 | |
| Weighted average score | 7.8 | |||
| METRIC | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Total Revenue | 51M | 23M | 7M | 219M | 219M |
| Gross Profit | 49M | 19M | 3M | 214M | 214M |
| Operating Income | -63M | -134M | -327M | -159M | -159M |
| Net Income | -59M | -113M | -274M | -114M | -114M |
| EBITDA | -60M | -130M | -323M | -155M | -155M |
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | N/A | -20.74 | 1.0 |
| Next quarter | N/A | -11.77 | 1.0 |
| Current year | -83.39 | -210.33 | 1.0 |
| Next year | 236.86 | 14.39 | 9.0 |
| Weighted average score | 3.0 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | -94.76 | -169.82 | -164.11 | -163.88 | 1.0 |
| Y/Y | 55.37 | 36.1 | 36.91 | 26.01 | 10 |
| 3y average | 966.77 | -58.98 | -15.84 | -24.25 | 3.3 |
| 5y average | 605.12 | -47.81 | -9.78 | -66.82 | 3.3 |
| Weighted average score | 4.4 | ||||
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | None | 1.0 |
| Intangible assets | None | 1.0 |
| Switching costs | None | 1.0 |
| Network effect | None | 1.0 |
| Economies of scale | None | 1.0 |
| Weighted average score | 1.0 | |
Company's cash reserves $112.8M significantly exceed its total debt $27.9M, ensuring strong financial flexibility
Total current assets $666.7M exceed Total current liabilities $58.8M, highlighting excellent liquidity
Debt-to-equity ratio (0.0) is well below the industry average (0.3), showcasing prudent financial management
Interest expense exists but EBIT data is unavailable, indicating potential profitability concerns
Negative free cash flow -$90.8M limits the company's ability to reinvest or pay down debt